Anthony Weido
Allergy & Immunology · Pasadena, TXNPI 1679570584
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,600 of the $31,276 with a category attached, or 78.7%. AstraZeneca accounts for 86.8% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $26,814 and has fallen 94.4% since, to $1,513 in 2025.
Across 271 payments — averaging $115.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- GSK$715
- CSL Behring$576
- Takeda Pharmaceuticals U.S.A., Inc.$519
- Regeneron Healthcare Solutions, Inc.$240
- Kaleo, Inc.$229
- plus $2K from 25 others
What the payments were for
- Consulting fees$600%
- Speaking & faculty fees$24,60079%
- Travel & lodging$7342%
- Food & beverage$5,86819%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $27,142 |
| GSK | 38 | $715 |
| CSL Behring | 25 | $576 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $519 |
| Regeneron Healthcare Solutions, Inc. | 11 | $240 |
| Kaleo, Inc. | 11 | $229 |
| Pfizer | 11 | $194 |
| Genentech USA, Inc. | 3 | $163 |
| Sanofi | 7 | $145 |
| Novartis | 7 | $145 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $143 |
| Optinose US, Inc. | 7 | $143 |
| Grifols USA, LLC | 7 | $140 |
| Octapharma USA, Inc. | 1 | $99 |
| Boehringer Ingelheim | 6 | $96 |
| LEO Pharma Inc. | 4 | $83 |
| Ionis Pharmaceuticals, Inc. | 2 | $69 |
| Blueprint Medicines Corporation | 3 | $67 |
| Pharming Healthcare, Inc. | 3 | $60 |
| Amgen | 3 | $50 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 4 | $29 |
| GC Biopharma USA, Inc. | 1 | $26 |
| Alk-abello, Inc | 2 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| ADMA Biomanufacturing LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,276 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $28,623 |
| Azelastine Hcl | 35 | $807 |
| Montelukast Sodium | 23 | $276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $715 | $28,62330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Pasadena
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
- Serge de GolovineBellaire$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.